Dual GIP/GLP-1 Agonist
Tirzepatide
Zepbound · Mounjaro · Eli Lilly
What is Tirzepatide?
Tirzepatide is a dual glucose-dependent insulinotropic polypeptide (GIP) and GLP-1 receptor agonist. By activating both receptors, it may produce greater weight loss than semaglutide alone. Clinical trials (SURMOUNT program) showed average weight loss of 20-22% over 72 weeks at maximum dose.
FDA Approval Status
FDA-approved: Zepbound for chronic weight management (2023), Mounjaro for type 2 diabetes (2022).
Dosing Schedule
2.5mg once weekly for 4 weeks, then increased by 2.5mg every 4 weeks to a maximum of 15mg/week.
Eligibility Criteria
Adults with BMI ≥30 kg/m², or BMI ≥27 kg/m² with at least one weight-related condition.
Common Side Effects
- Nausea
- Diarrhea
- Vomiting
- Constipation
- Stomach pain
- Decreased appetite
This is not a complete list. Discuss risks with your healthcare provider.
Compare Medications
Quick Facts
TypeDual GIP/GLP-1 Agonist
ManufacturerEli Lilly
RouteSubcutaneous injection
FrequencyOnce weekly
CompoundedAvailable